AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Hematologic disorder

Hodgkins lymphoma

A heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.

🔔 Follow weekly
🧬2932genes / proteins with evidence
💊201drugs and clinical candidates
🧪12+recruiting trials worldwide
✅18approved
📈37phase 3
🧬

Understand Hodgkins lymphoma

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Hodgkin lymphoma, also called Hodgkin disease, is a type of cancer that develops in the lymph system. Your lymph system is part of your immune system. It helps protect your body from infection and disease.

The lymph system is made up of tissues and organs that produce, store, and carry white blood cells. It includes your:

Bone marrow

From MedlinePlus: Hodgkin Lymphoma (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for Hodgkins lymphoma itself.

🤖

AI briefing

Where the science on Hodgkins lymphoma stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens Hodgkins lymphoma.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
PDCD1 programmed cell death 1PROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.61
TNFRSF8 TNF receptor superfamily member 8PROTACantibodyother🧊 AlphaFold structure ↗ 0.61
TUBB3 tubulin beta 3 class IIIPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB tubulin beta class IPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB4B tubulin beta 4B class IVbPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB2B tubulin beta 2B class IIbPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA4A tubulin alpha 4aPROTACantibodyothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA1B tubulin alpha 1bPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA3C tubulin alpha 3cPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB8 tubulin beta 8 class VIIIPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA3E tubulin alpha 3ePROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB4A tubulin beta 4A class IVaPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBA1C tubulin alpha 1cPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB6 tubulin beta 6 class VPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59
TUBB1 tubulin beta 1 class VIPROTACothersmall molecule🧊 AlphaFold structure ↗ 0.59

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to Hodgkins lymphoma, by how far it has got
Approved · 18
BleomycinApproved
Bleomycin SulfateApproved
Brentuximab VedotinTubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agentApproved
CarmustineGlutathione reductase inhibitorApproved
ChlorambucilApproved
CyclophosphamideApproved
Show all 18
DacarbazineApproved
Doxorubicin HydrochlorideDNA topoisomerase II alpha inhibitorApproved
Gallium Citrate Ga 67Approved
LomustineApproved
MelphalanApproved
NivolumabProgrammed cell death protein 1 inhibitorApproved
PembrolizumabProgrammed cell death protein 1 inhibitorApproved
ProcarbazineApproved
SintilimabProgrammed cell death protein 1 antagonistApproved
ThiotepaApproved
TislelizumabProgrammed cell death protein 1 inhibitorApproved
Vinblastine SulfateTubulin inhibitorApproved
In phase 2 / 3 · 20
AldesleukinInterleukin-2 receptor agonistPhase 3
CisplatinPhase 3
CyclosporineCyclophilin A modulatorPhase 3
CytarabineDNA polymerase (alpha/delta/epsilon) inhibitorPhase 3
DexamethasoneGlucocorticoid receptor agonistPhase 3
DexrazoxaneDNA topoisomerase II inhibitorPhase 3
Show all 20
Dexrazoxane HydrochlorideDNA topoisomerase II inhibitorPhase 3
DoxorubicinDNA topoisomerase II alpha inhibitorPhase 3
EpirubicinPhase 3
EtoposideDNA topoisomerase II inhibitorPhase 3
Etoposide PhosphateDNA topoisomerase II alpha inhibitorPhase 3
FilgrastimGranulocyte colony stimulating factor receptor agonistPhase 3
Gemcitabine HydrochlorideRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 3
IfosfamidePhase 3
Interferon Alfa-2BInterferon alpha/beta receptor agonistPhase 3
Interferon Gamma-1BInterferon gamma receptor agonistPhase 3
MechlorethaminePhase 3
Mechlorethamine HydrochloridePhase 3
MethotrexateDihydrofolate reductase inhibitorPhase 3
MethylprednisoloneGlucocorticoid receptor agonistPhase 3
Early trials · 20
AfuresertibSerine/threonine-protein kinase AKT inhibitorPhase 1/2
Bendamustine HydrochloridePhase 1/2
Carfilzomib26S proteasome inhibitorPhase 1/2
ClofarabineRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Phase 1/2
DaclizumabInterleukin-2 receptor inhibitorPhase 1/2
DaratumumabLymphocyte differentiation antigen CD38 inhibitorPhase 1/2
Show all 20
GivinostatHistone deacetylase inhibitorPhase 1/2
IpilimumabCytotoxic T-lymphocyte protein 4 inhibitorPhase 1/2
LebrikizumabInterleukin-13 inhibitorPhase 1/2
LirilumabKiller cell immunoglobulin-like receptor 2DL1 inhibitor; Killer cell immunoglobulin-like …Phase 1/2
LucatumumabTumor necrosis factor receptor superfamily member 5 antagonistPhase 1/2
OmidubicelPhase 1/2
Pentetate Calcium TrisodiumPhase 1/2
Polatuzumab VedotinB-cell antigen receptor complex-associated protein beta chain binding agent; Tubulin inhi…Phase 1/2
PomalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitorPhase 1/2
PralatrexateDihydrofolate reductase inhibitorPhase 1/2
RelatlimabLymphocyte activation gene 3 protein inhibitorPhase 1/2
RicolinostatHistone deacetylase 6 inhibitorPhase 1/2
Sb-743921Phase 1/2
SorafenibSerine/threonine-protein kinase RAF inhibitor; Platelet-derived growth factor receptor be…Phase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaNCT07121946 · Phase 1 · 📍 DuarteConstitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasNCT06176690 · Phase 1 · 📍 HoustonIntrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Thera…NCT07763210 · Phase 2 · 📍 NashvilleDaratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castl…NCT05907759 · Phase 2 · 📍 BethesdaComparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHLNCT07234487 · Phase 2 · 📍 MoscowLong-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesNCT06508775 · NA · 📍 BerlinSynKIR-310 for Relapsed/Refractory B-NHLNCT06544265 · Phase 1 · 📍 DenverCART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's L…NCT05054257 · Phase 1 · 📍 PragueR-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor BurdenNCT05040555 · NA · 📍 ChangchunA Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's LymphomaNCT07439653 · Phase 1, Phase 2 · 📍 FullertonAn Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection…NCT07101705 · EARLY Phase 1 · 📍 WuhanTesting the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Tre…NCT06015880 · Phase 1 · 📍 Duarte Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy